ENDUR-ACIN® Wax Matrix Niacin is an extended-release dietary supplement featuring SmartMatrix™ tablet technology. Each tablet dissolves slowly over 6 to 8 hours for a gradual release of nicotinic acid at the preferred rate to support blood cholesterol and lipid balance and help eliminate the nuisance "niacin skin flush” and digestive upset common with regular immediate-release formulas. 

Researchers attribute the ability of nicotinic acid to modulate cholesterol and lipid metabolism primarily to its action on liver cells (hepatocytes) and, to a lesser extent, on fat cells (adipocytes). 

In liver cells, nicotinic acid has been shown to inhibit the enzyme diacylglycerol O-acyltransferase 2 (DGAT2), an action that supports normal triglyceride production and cholesterol metabolism (1). 

On fat cells, nicotinic acid has been shown to bind to hydroxycarboxylic acid receptor 2 (HCA2), an action that inhibits the release of free fatty acids into the bloodstream (2). 

Directions: As a dietary supplement for adults, take one (1) to four (4) tablets, twice daily, with food. Use only as directed by your healthcare professional. 

ENDUR-ACIN® is backed by a robust research portfolio. The efficacy, safety and tolerance of ENDUR-ACIN® has been evaluated in 24 studies—including 17 clinical trials. This award-winning cardiovascular support supplement has been shown to be well tolerated and clinically effective for supporting cholesterol and lipid balance, either alone or as a complement to other interventions (3). 

ENDUR-ACIN® dosages of 1,500 to 2,000 mg/day, taken for 8 to 38 weeks, have been shown to be well tolerated and effective for cholesterol and lipid balance, especially in older adults (3,4). 

ENDUR-ACIN® Research Portfolio 

• 17 Clinical Trials - (Cholesterol & Lipid Balance) 
• 4 Analytical Studies - (Pharmacokinetic, Dissolution, Free Nicotinic Acid, Cost analysis) - 1 Systematic Review 
• 1 Post-Hoc Analysis - (Cholesterol & Lipid Balance) 
• 1 Case Series - (Healthy Aging Protocol) 

ENDUR-ACIN® Wax Matrix Niacin 

Extended-release and immediate-release products are not interchangeable. The average therapeutic dosage of Endur-Acin® (1,000 to 2,000 mg/day) for cholesterol and lipid support is about half the dosage of immediate-release nicotinic acid (3,000 mg/day) and typically does not exceed 2,000 mg/day. 

• Preferred dissolution rate. Dissolution data confirm ENDUR-ACIN® has the preferred dissolution profile to support optimal cholesterol and lipid balance (6). The primary absorption of nicotinic acid is during the first 2-3 hours after dosing with absorption essentially complete by 6 hours (6). 
• Helps avoid nuisance skin flush. In clinical trials of ENDUR-ACIN®, the dropout rate due to side effects such as skin flushing, digestive upset, itching, and other minor reactions was very low—about 4%—which supports its excellent tolerability. 

Other Ingredients: Vegetable wax (rice bran and/or carnauba), stearic acid (vegetable), magnesium stearate (vegetable), and silica. 

Consult your healthcare professional prior to use if you have or suspect a medical condition, are taking any medications, or are pregnant or nursing. Temporary flushing, itching or warming of the skin may occur. Do not use without the advice of your physician if you consume more than modest amounts of alcohol, have poorly controlled diabetes, liver disease, gout, active peptic ulcer disease, or unstable angina. 

ENDUR-ACIN® Wax Matrix Niacin (Nicotinic Acid) is manufactured in the United States (Oregon) in a state-of-the-art, FDA-registered facility that meets or exceeds current Good Manufacturing Practices (cGMP). Quality control tests are performed at every stage of the manufacturing process from rigorous raw material testing to finished product testing. 

1. Ganji SH, et al.. J Lipid Res. 2004;45(10):1835-1845. 
2. Lukasova M, et al. Trends Pharmacol Sci. 2011;32(12):700-707. 
3. Dunatchik AP, et al. J Clin Lipidol. 2012;6(2):121-31. 
4. Keenan JM, et al. J Am Geriatr Soc. 1992;40(1):12-18. 
5. Poon IO, et al. Am J Health Syst Pharm. 2006;63(21):2128-34. 
6. Keenan JM. J Clin Lipidol. 2013;7(1):14-23.